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Abstract With enhanced surgical techniques and neoadju-
vant therapy in rectal cancer, survivorship issues are at the
forefront of clinical practice and research. More and more
patients are living with altered bowel habits following rectal
cancer surgery. Sound assessment of anorectal function after
rectal cancer surgery is the foundation for the continuing effort
to explore the adverse effects of such surgery on bowel
function, as well as for working towards reducing these ef-
fects. The quality of the assessment is predominantly deter-
mined by the instrument administered. This article reviews
various questionnaires for capturing anorectal function after
surgery in rectal cancer, discussing their attributes and suit-
ability for different evaluation contexts.
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Introduction
Rectal cancer is common and poses much burden worldwide [1,
2]. Advances in treatment over the past three decades have led to
substantially improved local control and survival [3–7].
Furthermore, the increasing use of sphincter-preserving resection
with a low colorectal or coloanal anastomosis has resulted in
fewer patients requiring a permanent colostomy, and it has
become the standard surgery for mid and low rectal cancers
[8–11].
Unfortunately, numerous patients experience anorectal, uri-
nary, and/or sexual dysfunction after sphincter-preserving resec-
tion for rectal cancer [12•, 13•, 14–17], with anorectal dysfunc-
tion being the commonest, especially when the surgery is com-
bined with radiotherapy [12•, 18–23].
Low Anterior Resection Syndrome
Anorectal or bowel dysfunction after sphincter-preserving
surgery manifests itself in a wide spectrum of symptoms,
including fecal incontinence, increased stool frequency, ur-
gency, and emptying difficulties. The complex of symptoms is
often collectively referred to as anterior resection syndrome
(ARS) or low anterior resection syndrome (LARS), named
after the low anterior resection procedure [24]. Previously
thought to be transient, LARS symptoms have been shown
to persist for years after resection, suggesting that LARS is
more of a permanent phenomenon [13•, 25]. These symptoms
usually appear immediately after surgery, becoming most
pronounced during the first few months, and improve some-
what thereafter, reaching a steady state after around one to
two years [26].
Although LARS has been well recognized, it has not been
clearly defined, with a large variation in the prevalence re-
ported. LARS has been reported to affect up to 60–90 % of
patients following low or ultralow anterior resection [13•, 24,
27–31], and can have a considerable impact on quality of life
(QOL) [26, 30, 32–35]. Recently, a pragmatic definition of
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LARS has been proposed as “disordered bowel function
after rectal resection, leading to a detriment in quality of
life” [13•].
Assessment of Anorectal Function After Rectal Cancer
Surgery
Even though anorectal function, like other types of physical
function, can be evaluated objectively to a certain extent, the
patient’s own rating should be the gold standard, as only the
patient can experience the function and perceive its true im-
plications in the context of his or her life [36, 37]. A newly
published study has demonstrated that even rectal cancer
experts do not have a thorough understanding of which
LARS symptoms truly matter to the patient, nor how these
symptoms affect QOL, thus emphasizing the necessity of
assessing anorectal function from the patient’s perspective
[38].
Nonvalidated or Unfitting Instruments
Many patient questionnaires or instruments have been
used for assessing anorectal function after rectal cancer
surgery. However, as highlighted in a systematic review
and meta-analysis of long-term bowel function after
curative anterior resection for rectal cancer, such assess-
ment has been inconsistent due to the lack of a uniform
definition of LARS, and the use of a large variety of
nonvalidated questionnaires [12•]. It was found that 65
% of the studies included (48 studies in the qualitative
analysis and 43 studies in the meta-analysis) did not use
a validated assessment instrument [12•].
On the other hand, there are some anorectal function
questionnaires that have been more rigorously tested,
yet are not entirely suitable to be administered after
surgery in rectal cancer; for instance, the American
Medical Systems fecal incontinence scoring system
[39], which was formulated for assessing the function
of artificial anal sphincters, and the Bowel Function
Questionnaire (BFQ) [40, 41], which focuses on symp-
toms during and after pelvic radiotherapy, as well as
those caused by pharmacologic agents, instead of sur-
gery [40–44].
A number of established bowel function-related QOL in-
struments, such as the European Organisation for Research
and Treatment of Cancer Quality of Life Questionnaire
Colorectal Module (EORTC QLQ-CR29) [45], the Fecal
Incontinence Quality of Life Scale (FIQL) [46], and the
Functional Assessment of Cancer Therapy – Colorectal
(FACT-C) [47], have often been used to supplement the eval-
uation of anorectal function following surgery in rectal cancer,
and to validate anorectal function questionnaires. This is be-
cause anorectal function questionnaires may only provide
insight into symptoms, and not insight into how the patient
is coping with the symptoms or how the patient’s life is
disrupted by the symptoms. Although these various QOL
instruments do contain some questions enquiring directly
about anorectal function, they also contain questions on other
matters. More importantly, although the fundamental con-
structs of function and QOL are related (function, as reflected
in dysfunction symptoms, is a component and determinant of
overall QOL), they are not the same [48, 49], and it would be
conceptually flawed to use instruments designed for measur-
ing the effects of bowel issues on QOL to specifically capture
anorectal function.
There are questionnaires that would be more appropri-
ate than those mentioned above for capturing anorectal
function after surgery in rectal cancer. The rest of this
article appraises these various validated and more fitting
instruments.
Fecal Incontinence Instruments
Fecal incontinence has long been the central focus of bowel
dysfunction in general. In keeping with this, several well-
known fecal incontinence questionnaires have been used in
different studies to evaluate incontinence in LARS patients
[50–57], including the Cleveland Clinic Florida (CCF)/
Wexner Fecal Incontinence Score (Wexner score; 1993) [58],
the St.Mark’s Incontinence Score (St.Mark’s score; 1999) [59],
and the Fecal Incontinence Severity Index (FISI; 1999) [60].
The Wexner score is the most widely applied fecal incon-
tinence instrument to date. It examines the frequency of three
types of fecal incontinence (solid, liquid, and gas) and their
consequences (pad wearing and lifestyle alteration). For each
item, the five frequency options range from never (score 0)
through to always (meaning at least once per day; score 4).
The total score is the sum of the item scores, and ranges from 0
(perfect continence) to 20 (complete incontinence).
The St. Mark’s score is built on the Wexner score, incorpo-
rating three modifications [59]. Firstly, an urgency item (lack
of ability to defer defecation for 15 min) was introduced, with
dichotomous response options of no (score 0) and yes (score
4). Secondly, an item on antidiarrheal drugs (use of constipa-
tion medicines) was added, again with dichotomous response
options of no (score 0) and yes (score 2). Lastly, it was thought
that pad wearing should not be given the same emphasis as the
incontinence items, because it is probably a measure of the
patient’s degree of fastidiousness, instead of the severity of
fecal incontinence [59]. Accordingly, the response options and
scoring of the pad wearing item were adjusted to no (score 0)
and yes (score 2). The total St. Mark’s score ranges from 0
(perfect continence) to 24 (complete incontinence).
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The FISI investigates the frequency of four types of fecal
incontinence (gas, mucus, liquid, and solid). There are six
frequency options for every item, ranging from never through
to two or more times per day. The score value of each incon-
tinence type/frequency combination is derived from its sever-
ity ranking relative to other combinations, as rated by 34
patients and 26 colorectal surgeons. Therefore, two sets of
scoring are available: a patient-based system and a surgeon-
based system, with the patient-based system being more
broadly used. The total score is the sum of the item scores,
and the patient-based score ranges from 0 (no incontinence) to
61 (severe incontinence).
All three instruments were developed empirically, on the
basis of known components of fecal incontinence [58–60].
They have been validated to varying extents, with the Wexner
score being the least rigorously validated of the three, despite
it being the most widely used. All three instruments have been
proven to correlate with the patient’s subjective perception of
bowel control [60–62]. They take on the same approach of
assessing the frequency of incontinence episodes. This ap-
proach implies that frequency corresponds to severity, which
may not always be the case. A minor symptom may occur
often, but this does not mean that the symptom is severe. For
example, a patient who experiences very slight leakage of
liquid stool on a daily basis would score higher on these
instruments compared with a patient who experiences leakage
of a large amount of liquid stool every two days. The latter
patient may not necessarily have better anorectal function,
contrary to the impression given by these instruments.
Both the Wexner score and the St. Mark’s score use a
linear scale for scoring the frequency of incontinence epi-
sodes, giving zero points to a symptom never occurring, one
point to it occurring rarely (less than once per month), two
points to it occurring sometimes (at least once per month but
less than once per week), and so forth. This kind of scale
assumes that the increase in anorectal dysfunction is linear
throughout the response range. It also assumes that there is a
linear correlation between the frequency a the symptom and
its level of bother. However, evidence shows that there is a
nonlinear relationship between symptom frequency and
bother in patients with neurogenic bowel dysfunction [63].
In addition, in scoring the Wexner score and the St. Mark’s
score, the different types of incontinence take on the same
weighting, but the fact is that they (for example, inconti-
nence for flatus vs. incontinence for solid stool) do not carry
the same significance of anorectal dysfunction for either the
patient or the clinician. Unlike the Wexner score and the St.
Mark's score, the FISI uses patient- and surgeon-rated score
values, and does not rely on a linear scale nor equal-
weighting scoring.
The FISI uses a one month recall period, asking the
patient to answer according to how often the symptom
is experienced on average in the past month. In
contrast, the Wexner score and the St. Mark's score do
not specify a recall period. A recall period helps to
evoke the patient's memory and ensures that the most
up-to-date status is captured. Nonetheless, in some situ-
ations, a recall period may result in the response not
being a fair representation of the patient's usual status,
such as if the patient is currently having or has recently
had an infection affecting bowel function.
The most critical point to note about applying any fecal
incontinence instrument to measure anorectal function after
surgery in rectal cancer is that they only reveal the continence
aspect. Because LARS is a disorder with heterogeneous
symptoms and involves more than just incontinence, fecal
incontinence instruments would not be able to fully capture
the complexity of the problem.
The Memorial Sloan-Kettering Cancer Center Bowel
Function Instrument
TheMemorial Sloan-Kettering Cancer Center Bowel Function
Instrument (MSKCC BFI; 2005) is the first questionnaire
designed specifically for evaluating bowel function after
sphincter-preserving surgery for rectal cancer [64••]. It consists
of 18 questions that enquire about the frequency of a variety of
LARS issues. The MSKCC BFI adopts a four-week recall
period, a linear scale, and equal-weighting scoring. For each
question, the five frequency options range from never through
to always (except for one question asking about the number of
bowel movements per 24 hours). Response can be summarized
into three subscales (frequency, six items; diet, four items; and
urgency/soilage, four items) by adding the scores of the items
in the subscale. The four single items that do not belong to a
subscale look into incomplete evacuation, clustering (having
another bowel movement within 15min of the last movement),
knowing the difference between needing to pass gas and a
bowel movement, and incontinence for flatus. A global score
can be calculated as the sum of the subscale scores, and a total
score can be calculated by adding all the item scores (subscale
plus single item scores). A higher score represents better bowel
function. Some item scores require recoding before they can be
used for computation.
The MSKCC BFI was meticulously formulated ac-
cording to literature review, expert and patient input,
factor analysis, and clinical relevance [64••]. Its psycho-
metric precision, including the ability to detect differ-
ences in bowel function based on clinical variables, was
confirmed through stringent validation [64••]. It has
been translated from English into Italian, and this ver-
sion has also been validated [65].
The main strengths of the MSKCC BFI are its scope
and detail, allowing comprehensive and thorough eval-
uation of LARS. The subscales facilitate separate
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interpretation of different aspects of LARS when de-
sired. However, the MSKCC BFI's length (18 questions)
and scoring (which involves recoding, three subscale
scores, a global score, and a total score) may influence
its practicality.
The Low Anterior Resection Syndrome Score
The Low Anterior Resection Syndrome Score (LARS score;
2012), like the MSKCC BFI, is a questionnaire for assessing
bowel function after sphincter-preserving surgery with or
Fig. 1 The LowAnterior Resection Syndrome Score (LARS score). (FromEmmertsen and Laurberg [66••] with permission fromWolters Kluwer Health)
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without radiotherapy for rectal cancer [66••]. The items and
scoring algorithm of the LARS score are shown in Fig. 1.
The LARS score was developed from and validated on a
large, nationwide cohort of 961 Danish patients, who received
curative low anterior resection with or without radiotherapy
for nondisseminated rectal cancer in Denmark between 2001
and 2007 [66••]. By applying binomial regression on patient
response, the five most bothersome LARS issues (both in
terms of prevalence and impact on QOL), with at least one
issue depicting each of the four known aspects of LARS
(incontinence, frequency, urgency, and emptying difficulties),
were selected for the LARS score from a pool of items
extracted from existing bowel function questionnaires and
the literature [66••]. The five issues selected are incontinence
for flatus, incontinence for liquid stool, frequency (number of
daily bowel movements), clustering (having to open bowels
again within 1 h of the last opening), and urgency. The ques-
tions enquire about the frequency of symptom episodes. The
LARS score does not use a specific recall period, a linear scale,
nor equal-weighting scoring. The response score values, also
derived using binomial regression, are based on the impact of
the particular symptom/frequency combination onQOL [66••].
The ability of the LARS score to reflect the impact of bowel
dysfunction on QOL was proven in its initial validation [66••],
and subsequently through the association with many of the
scales of the European Organisation for Research and
Treatment of Cancer Quality of Life Questionnaire Core
Module (EORTC QLQ-C30) [26, 67]. The impact on QOL is
pertinent when assessing bowel dysfunction, because a mere
description of the symptoms may not necessarily differentiate
between patients with acceptable function and patients in need
of further attention. In clinical settings, the LARS score severity
categories (No, Minor, and Major LARS) can facilitate quick
identification of patients most in need of treatment, namely
those with Major LARS, since they also report seriously com-
promised QOL, and significantly worse QOL compared with
those with No/Minor LARS [26, 66••, 67]. Moreover, the
LARS score has demonstrated the ability to differentiate be-
tween subgroups of patients on the basis of clinical variables
[66••]. In addition to the original Danish version, the LARS
score has been translated into several other languages (English,
Dutch, Swedish, Spanish, and German: validation is in progress
for the former two, and the latter three have been validated in an
international setting) [68], and hence has the capacity for wide-
spread use.
The biggest strengths of the LARS score lie in its concise-
ness and ability to show impact on QOL. Its ease of scoring
and clinically meaningful severity categories further support
its routine use in clinical practice.
Urgency and clustering are the items with the highest
response score values in the LARS score, indicating that these
aspects of LARS affect the patient’s QOL the most. This
reinforces the reasoning that fecal incontinence instruments
and equal-weighting scoring would not be able to fully reflect
LARS as experienced by the patient.
Conclusions
Rectal cancer surgery is now performed with relatively good
oncologic outcomes and the avoidance of a permanent colos-
tomy in most cases. Nevertheless, many patients are plagued
by LARS after such surgery. Sound assessment of anorectal
function after rectal cancer surgery is the foundation for con-
tinuing to elucidate the true characteristics and incidence of
LARS, for further improving surgical techniques to prevent
LARS, and for trialing and consolidating the treatment of
LARS. The quality of the assessment lies primarily in the
questionnaire used.
Given that LARS is such a common problem that often leads
to poor QOL, all patients should be routinely screened for LARS
after sphincter-preserving surgery, and the level of anorectal
function should be systematically recorded for benchmarking
and quality improvement purposes. Consequently, routine and
widespread assessment of LARS is called for.
In summary, the instruments appraised in this article have
strengths and weaknesses that make up their own unique
“attribute profile.” This profile determines the measurement
context for which the instrument is most suitable.
For focused assessment of fecal incontinence, the
Wexner score, the St. Mark’s score, and the FISI would
all be adequate. Among the three instruments, the scoring
and validation of the FISI are the most methodologically
rigorous. It is vital that the application of fecal inconti-
nence questionnaires is supported by proper rationale and
accurate understanding of their limitations in painting the
full picture of LARS.
For comprehensive and in-depth evaluation of LARS, the
MSKCC BFI would be the questionnaire of choice. For rapid
screening or assessment of LARS, the LARS score would be
ideal. Both instruments are valid, reliable, and able to detect
clinically relevant differences.
The use of one instrument does not preclude the use of
another, and there may be situations where it is beneficial to
use a combination of the aforementioned instruments.
All things considered, the MSKCC BFI and the LARS
score are the best questionnaires to capture anorectal function
after surgery in rectal cancer. Although there is some overlap
in content, the two instruments are fundamentally different.
Overall, the scope of theMSKCCBFI is broader, covering not
only LARS symptoms, but also their consequences, such as
diet limitations and pad wearing. On the other hand, the LARS
score is more practical, and can indicate impact on QOL.
Finally, the adoption of a uniform definition of
LARS, and the consistent use of the same question-
naires that best serve the particular measurement context
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and aim, are greatly encouraged, in order to pool and
directly compare results of different studies, institutions,
and interventions.
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